DEVELOPMENT AND MANUFACTURE OF PERS BUDDY Clause Samples

DEVELOPMENT AND MANUFACTURE OF PERS BUDDY. 2.1 Set forth in Attachment III(A) hereto is a functional product description for the PERS BUDDY to be developed hereunder. HEALTH HERO and AMAC shall develop, test and validate the PERS BUDDY in accordance with the final, detailed product specifications, tasking and development schedule set forth in Attachment III(B) hereto, such Attachment III(B) to be developed and agreed within 90 days after the Effective Date. Among other things, Attachment III(B) will delineate the parties' respective responsibilities regarding development of the PERS BUDDY. Development of the PERS BUDDY by HEALTH HERO and AMAC shall be in three (3) phases as set forth in Attachment III(B), and in accordance with milestone deliverables to be met by HEALTH HERO and AMAC in developing the PERS BUDDY during such three phases, as set forth in Attachment IV hereto. The results of such development, testing and validation will be submitted in writing to AMAC for its review and written approval (not to be unreasonably withheld or delayed) prior to the commercial manufacture or marketing of the PERS BUDDY. In no event will any data generated by the PERS components or PERS features of the PERS BUDDY be transferred or transmitted using any part of the HEALTH HERO communication network 2.2 AMAC may request HEALTH HERO to carry out development work, or provide AMAC with technical assistance in developing and manufacturing the PERS BUDDY, that (a) is a change to, or is in
View Source

Related to DEVELOPMENT AND MANUFACTURE OF PERS BUDDY

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection ▇▇▇▇▇; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Collaboration activities 4.1 The Collaboration Suppliers will perform the Collaboration Activities and all other obligations of this Agreement in accordance with the Detailed Collaboration Plan. 4.2 The Collaboration Suppliers will provide all additional cooperation and assistance as is reasonably required by the Buyer to ensure the continuous delivery of the services under the Call-Off Contract. 4.3 The Collaboration Suppliers will ensure that their respective subcontractors provide all cooperation and assistance as set out in the Detailed Collaboration Plan.

  • PROJECT WORK PLAN The Statement of Work is the formal document incorporated into the Grant. The Project Work Plan documents how the Grantee will achieve the performance measures outlined in the Grant. Changes to the Statement of Work require an amendment. Project Work Plans may be changed with written approval from DFPS and the Grantee.

  • Development Work The Support Standards do not include development work either (i) on software not licensed from CentralSquare or (ii) development work for enhancements or features that are outside the documented functionality of the Solutions, except such work as may be specifically purchased and outlined in Exhibit 1. CentralSquare retains all Intellectual Property Rights in development work performed and Customer may request consulting and development work from CentralSquare as a separate billable service.